Dermatologic Toxicity of Chemotherapeutic Agents
Authors:
- Aimee S. PayneAPAimee S. Payne
- William D. JamesWJWilliam D. James
- Raymond B. WeissRWRaymond B. Weiss
- 1 February 2006
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 33 (1) , 86-97
Abstract
No abstract availableKeywords
This publication has 124 references indexed in Scilit:
- Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancersGynecologic Oncology, 2005
- Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburnGynecologic Oncology, 2004
- Gemcitabine-associated scleroderma-like changes of the lower extremitiesJournal of the American Academy of Dermatology, 2004
- Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumoursBritish Journal of Dermatology, 2004
- The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma1Gynecologic Oncology, 2004
- Host‐vs.‐altered‐host eruptions in patients on liposomal doxorubicinJournal of Cutaneous Pathology, 2002
- Fixed drug eruption induced by trimethoprim-sulfamethoxazole: Evidence for a link to HLA-A30 B13 Cw6 haplotypeJournal of the American Academy of Dermatology, 2001
- Docetaxel extravasationSupportive Care in Cancer, 2001
- Hypersensitivity to paclitaxel manifested as a bullous fixed drugeruptionJournal of the American Academy of Dermatology, 1996
- Cutaneous reactions to recombinant cytokine therapyJournal of the American Academy of Dermatology, 1995